

¹**Factors associated with variation in single-dose albendazole**

²**pharmacokinetics: A systematic review and modelling analysis**

³**Short title: Review and modelling of albendazole pharmacokinetics**

- 4 Charles Whittaker^{1,5,§}, Cédric B. Chesnais², Sébastien D.S. Pion², Joseph Kamgno³, Martin
- 5 Walker^{4,5}, Maria-Gloria Basáñez^{1,5*} & Michel Boussinesq^{2*}
- 1^{th} MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease
- ⁷Epidemiology, School of Public Health, Imperial College London, London, UK
- 2^2 Institut de Recherche pour le Développement (IRD), Montpellier, France
- ³ Centre for Research on Filariasis & other Tropical Diseases, and Faculty of Medicine and
- 10 Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
- ⁴ Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, UK
- ⁵ London Centre for Neglected Tropical Disease Research, Department of Infectious Disease
- ¹³Epidemiology, School of Public Health, Imperial College London, London, UK
- 14 * Joint senior authors
- **§** 15 Sorresponding author: charles.whittaker16@imperial.ac.uk

16

C. Whittaker et al. Albendazole Pharmacokinetics 2

¹⁷**Abstract**

¹⁸**Background**

¹⁹Albendazole is an orally administered anti-parasitic medication with widespread usage in a 20 variety of both programmatic and clinical contexts. Previous work has shown the drug to be 21 characterised by significant inter-individual pharmacokinetic variation. This variation is 22 thought to have important consequences for treatment success, but current understanding of 23 the factors associated with this variation remains incomplete.

²⁴**Methodology/Principal Findings**

²⁵We carried out a systematic review to identify references containing temporally 26 disaggregated data on the blood concentration of albendazole and/or (its pharmacologically-27 active metabolite) albendazole sulfoxide following a single oral dose. These data were then 28 integrated into a mathematical modelling framework to infer key pharmacokinetic parameters 29 and relate them to characteristics of the populations being treated. These characteristics 30 included age, weight, sex, dosage, infection status, and whether patients had received a fatty ³¹meal prior to treatment or other drugs alongside albendazole. Our results highlight a number 32 of factors systematically associated with albendazole pharmacokinetic variation including ³³age, existing parasitic infection and receipt of a fatty meal. These factors impact different 34 aspects of the drug's pharmacokinetic profile. Whilst age is significantly associated with 35 albendazole sulfoxide half-life, receipt of a fatty meal prior to treatment was associated with 36 increased albendazole bioavailability (and by extension, peak blood concentration and total ³⁷drug exposure following the dose). Parasitic infection (particularly echinococcosis and ³⁸neurocysticercosis) was associated with altered pharmacokinetic parameters, with infected 39 populations displaying distinct characteristics to uninfected ones.

⁴⁰**Conclusions/Significance**

⁴¹These results highlight the extensive inter-individual variation that characterises albendazole 42 pharmacokinetics and provides insight into some of the factors associated with this variation.

⁴³**Key-Words:** Albendazole, Albendazole sulphoxide, Single-dose, Pharmacokinetics, ⁴⁴Systematic review, Modelling, Inter-individual variation

C. Whittaker et al. Albendazole Pharmacokinetics 3

⁴⁶**Author Summary**

⁴⁷Albendazole is a broad-spectrum anti-parasitic medication widely used in the treatment of a 48 variety of parasitic worm infections. Previous studies have demonstrated significant variation ⁴⁹in the pharmacokinetics of albendazole (and its pharmacologically active metabolite 50 albendazole sulfoxide), leading to substantial inter-individual variability in blood plasma 51 concentrations following a dose of the drug being given. This variation is thought to have 52 important consequences for treatment success but our understanding of the factors driving 53 this variation remain incomplete. In this study, we carried out a systematic review to identify 54 references with data on albendazole and albendazole sulfoxide concentrations in the blood ⁵⁵following a single oral dose. We then fitted a mathematical model of albendazole 56 pharmacokinetics to these data to infer key pharmacokinetic parameters and relate them to 57 characteristics of the populations being treated. We found that receipt of a fatty meal prior to 58 treatment was associated with increased albendazole bioavailability, that the half-life of 59 albendazole sulfoxide in the blood varied significantly with age, and that both echinococcosis ⁶⁰and neurocysticercosis were associated with altered pharmacokinetic profiles compared to 61 healthy individuals. Our work provides insight into some of the factors systematically 62 associated with variation in albendazole pharmacokinetics.

63

C. Whittaker et al. Albendazole Pharmacokinetics 4

⁶⁴**Introduction**

Albendazole is a broad-spectrum medication used widely in the treatment of a variety of parasitic worm infections. This includes usage in a clinical context, where multiple-dose regimens are used to treat infections with the larval stages of *Taenia solium* ((neuro-)cysticercosis) [1] or of *Echinococcus* spp. (principally cystic and alveolar echinococcosis due to, respectively, *E. granulosus* and *E. multilocularis*) [2]. It has also been used extensively in neglected tropical disease (NTD) 70 programmatic contexts, for which albendazole is being/has been delivered (as a single-dose treatment) 71 to communities in mass drug administration (MDA) campaigns against soil-transmitted helminthiases [3] (STHs, due to *Ascaris lumbricoides*, *Trichuris trichiura*, *Necator americanus* and/or *Ancylostoma duodenale*), and delivered alone [4] or alongside ivermectin and/or diethylcarbamazine [5,6]) against lymphatic filariasis [7] (LF, due to *Wuchereria bancrofti* or *Brugia malayi*). In addition, albendazole has also been offered to individuals with loiasis [8,9], frequently those whose *Loa loa* microfilarial 76 densities are high enough to preclude safe treatment with microfilaricidal anthelmintics $[10,11]$ (such 77 as diethylcarbamazine or ivermectin [12]).

⁷⁸Whilst the therapeutic efficacy of albendazole has been established for a wide array of helminth 79 parasites, the drug's pharmacokinetics (and those of its pharmacologically-active metabolite, 80 albendazole sulfoxide) are characterised by extensive inter- and intra-individual variation. This 81 variation has been consistently observed across a wide range of studies (see [13] for a review and its 82 implications for treatment), and is typically attributed to the drug's limited solubility in the 83 gastrointestinal tract and extensive first-pass metabolism by the liver (responsible for rapid conversion 84 of albendazole to albendazole sulfoxide). This variation is thought to contribute to the failure of cure 85 in some treated patients – whilst some require only one course of treatment, others require multiple 86 rounds and, in a limited number of instances, treatment failure has been observed [13–15]. This 87 variation in outcomes observed in clinical settings has also been seen in field studies, where highly 88 variable impact of the drug on STH infections have been observed depending on the setting [16]. For 89 example, the average reduction in faecal egg reduction rates for treated hookworm infections varied 90 from 53% to 95% across different communities in Ghana [17] (though note that such observations

C. Whittaker et al. Albendazole Pharmacokinetics 5

91 might also be driven by variation between settings in the prevalence of different STH species which

92 are thought to show variable responses to albendazole treatment [18]).

⁹³A number of factors are deemed to underlie this variation in pharmacokinetic dynamics. Several 94 studies have examined the influence of different drivers, including sex [19], co-administered drugs ⁹⁵[20,21], delivery of albendazole alongside a fatty meal [22,23] and infection status [24,25] on the 96 pharmacokinetic profile of albendazole and/or albendazole sulfoxide. However, these studies typically 97 only analyse a single factor, and therefore a systematic understanding of the comparative impact of 98 different factors on albendazole's pharmacokinetics remains outstanding. Given albendazole's ⁹⁹widespread usage in NTD programmatic contexts, insight into mechanisms that influence the 100 pharmacokinetic profile of albendazole could have significant public health relevance.

101 Motivated by this, we conducted a systematic review of the literature to identify references containing 102 temporally disaggregated information on albendazole and/or albendazole sulfoxide concentrations in 103 the blood following treatment with a single oral dose (the typical regimen used in NTD programmatic 104 contexts). To these data, we fitted a mathematical model of albendazole and albendazole sulfoxide's 105 dynamics in the blood following receipt of the dose that captures key phenomena associated with the 106 drug's metabolism. These include albendazole's extensive first-pass metabolism [26] and its 107 established low bioavailability [27]. We fitted this model to data collated as part of the systematic 108 review to infer key pharmacokinetic parameters, including albendazole bioavailability, albendazole 109 sulfoxide half-life, peak albendazole concentration in the blood (C_{Max}) and the total drug exposure 110 across time (commonly described as the area under the curve or *AUC*). We then related these 111 parameter estimates to characteristics of the patient populations being treated and the treatment 112 regimen received.

¹¹³**Methods**

¹¹⁴**Systematic review of albendazole pharmacokinetic literature**

115 Web of Science and PubMed databases were searched on $4th$ July 2019 with no limitations on date 116 range using the keywords "albendazole" AND (treatment* OR dose* OR pharma* OR "half-life" OR

C. Whittaker et al. Albendazole Pharmacokinetics 6

¹¹⁷"half life") in order to identify references containing temporally disaggregated data detailing the 118 concentration of albendazole and/or albendazole sulfoxide in the blood following treatment with a 119 single dose of the drug. A total of 5690 unique records were identified through this search process, ¹²⁰with 206 records retained for full text evaluation following Title and Abstract screening **(Fig 1)**. 121 Studies lacking the required information on blood concentration levels over time, that had been 122 carried out *in vitro* or in non-human subjects, or were not in English were subsequently excluded. ¹²³Following this, a total of 32 references were included, yielding 92 time-series describing the evolution 124 of blood concentrations of albendazole and/or albendazole sulfoxide following treatment with a single 125 dose. Fifteen time-series contained information on both albendazole and albendazole sulfoxide levels; 126 and 77 contained information on albendazole sulfoxide levels only. Eighty-four of these time-series 127 were studies in which only blood drug concentrations following a single oral dose of albendazole 128 were presented; and eight were studies in which measured blood drug concentrations were presented 129 that spanned a course of multiple doses, but that contained information on drug blood concentration 130 levels immediately following the first dose. For these eight time-series, we extracted data following ¹³¹receipt of the first dose up until receipt of the second dose. For each time-series, we also extracted the 132 data describing evolution of albendazole/albendazole sulfoxide levels over time, as well as an array of ¹³³metadata. These included characteristics of the treatment regimen (dose, fasting state, co-administered ¹³⁴drugs), as well as information and metadata on the patients receiving treatment (sex, age, infection 135 status and weight). In the majority of instances, presented data were reported for a population of 136 patients rather than individuals. In these instances, population averages for factors such as age, ¹³⁷weight, etc., were extracted. A full list of these references, as well as further information about each ¹³⁸study and how the data were extracted are available in *Supplementary S1 File, S1 Text: Data*

¹³⁹*Extraction, Collation and Initial Processing*.

140 **Fig 1: PRISMA diagram illustrating the systematic review workflow.** Web of Science and 141 PubMed were searched on 4th July 2019 using the keywords albendazole AND (treatment* OR dose* 141 PubMed were searched on $4th$ July 2019 using the keywords albendazole AND (treatment* OR dose* 142 OR pharma* OR "half-life" OR "half life"). This produced a total of 5690 results after duplicate 142 OR pharma* OR "half-life" OR "half life"). This produced a total of 5690 results after duplicate
143 removal, of which 206 were retained for full text screening. 175 of the retained articles were 143 removal, of which 206 were retained for full text screening. 175 of the retained articles were
144 subsequently excluded based on pre-defined exclusion criteria, yielding 32 studies containing 144 subsequently excluded based on pre-defined exclusion criteria, yielding 32 studies containing
145 temporally disaggregated data on albendazole blood concentrations following treatment with a single temporally disaggregated data on albendazole blood concentrations following treatment with a single

146 dose; these 32 references contained a total of 92 time-series measuring albendazole and/or albendazole sulfoxide blood concentrations over time in different populations. albendazole sulfoxide blood concentrations over time in different populations.

148

¹⁴⁹**Mathematical model construction and fitting**

¹⁵⁰We developed a model describing the evolution of albendazole and albendazole sulfoxide 151 concentrations in the blood following receipt of a single oral dose of the drug, based on a series of ¹⁵²linked ordinary differential equations (ODEs) of albendazole and its metabolite albendazole sulfoxide ¹⁵³**(Fig 2)**. The model incorporates a number of pharmacokinetic phenomena relevant to albendazole, 154 including its well-established, limited bioavailability (thought to be a product of its poor solubility 155 along the gastrointestinal tract [27]) and the extensive first-pass metabolism of albendazole to 156 albendazole sulfoxide known to occur in the liver [26]. This model was fitted individually to each of 157 the 92 collated time-series within a Bayesian framework, utilising an adaptive Metropolis-Hastings 158 based Markov Chain Monte Carlo (MCMC) sampling scheme for parameter inference. Uninformative 159 priors were used for each of the parameters being subsequently related to the collected metadata. For 160 each dataset, a total of 25,000 iterations were run, with the first 5,000 discarded as burn in, leaving 161 20,000 samples available for parameter inference – the median value based on these samples was then ¹⁶²used as an input into the multiple linear regression (described below). Further information on the ¹⁶³exact formulation of the model and the fitting process is available in *Supplementary S1 File, S2 Text:* ¹⁶⁴*Model Construction, Fitting and Inference*.

**Fig 2: Schematic representation of the model describing albendazole and albendazole sulfoxide
166 dynamics and pharmacokinetics.** A compartmental model consisting of a series of linked ordinary 166 **dynamics and pharmacokinetics.** A compartmental model consisting of a series of linked ordinary
167 differential equations (ODEs) was developed to simulate the pharmacokinetics of albendazole and its 167 differential equations (ODEs) was developed to simulate the pharmacokinetics of albendazole and its
168 pharmacodynamically-active metabolite, albendazole sulfoxide, in the blood following a single oral 168 pharmacodynamically-active metabolite, albendazole sulfoxide, in the blood following a single oral
169 dose. (A) Schematic representation illustrating the model structure and the way in which the different 169 dose. **(A)** Schematic representation illustrating the model structure and the way in which the different 170 compartments are linked. **(B)** Overview of the ODEs governing the model, representing the amount of 170 compartments are linked. **(B)** Overview of the ODEs governing the model, representing the amount of albendazole in the gut and concentration of the drug (and its metabolite albendazole sulfoxide) in the 171 albendazole in the gut and concentration of the drug (and its metabolite albendazole sulfoxide) in the 172 liver and systemic circulation. Note that the received dose is further scaled by a bioavailability 172 liver and systemic circulation. Note that the received dose is further scaled by a bioavailability 173 parameter not shown here (see *S1 File, S2 Text subsection:* **Mathematical Model of Albendazole** 173 parameter not shown here (see *S1 File, S2 Text subsection:* **Mathematical Model of Albendazole and Albendazole Sulfoxide Dynamics** for further details and full description of the model ¹⁷⁴**and Albendazole Sulfoxide Dynamics** for further details and full description of the model equations).

176

¹⁷⁷**Regression linking pharmacokinetic properties to patient characteristics**

C. Whittaker et al. Albendazole Pharmacokinetics 8

178 From the 92 fitted time-series, we extracted estimates of key pharmacokinetic parameters and 179 regressed them onto the collected metadata (describing aspects of the patient population and treatment 180 regimen received) to assess the influence of various factors on variation in albendazole and 181 albendazole sulfoxide's pharmacokinetics. The pharmacokinetic parameters were k_{AlbSO} (the half-life 182 of albendazole sulfoxide), the *bioavailability* of albendazole (the proportion of administered 183 albendazole absorbed from the gut into the blood), C_{Max} (the peak concentration of the drug in the 184 blood) and AUC ("area under the curve", reflecting the total exposure to the drug after administration 185 of the dose, calculated over a time-period of 50 hours). k_{AlbSO} and *bioavailability* are model 186 parameters directly estimated during the fitting process outlined above, and so for each time-series, 187 the median parameter estimate from each time-series was used in the regression. For C_{Max} and AUC , 188 in order to control for differences in dosages between studies (which would directly impact estimates 189 of these two quantities), we used the fitted model (and median parameter estimates) for each time-190 series to simulate and generate a hypothetical pharmacokinetic curve assuming a standardised dose of 191 400 mg. We then calculated C_{Max} and AUC from this hypothetical pharmacokinetic curve to give 192 estimates of the two parameters standardised by the dose received. We subsequently refer to these 193 quantities as C_{Max400} and AUC_{400} .

¹⁹⁴**Results**

¹⁹⁵**Systematic review results and study characteristics**

¹⁹⁶A total of 32 references containing 92 time-series detailing the concentration of albendazole and/or 197 albendazole sulfoxide in the blood following treatment with a single dose of albendazole were 198 identified. Forty-four time-series were data for a single individual and 58 time-series described 199 average concentrations through time for a group of individuals (mean group size $= 12.2$, interquartile 200 range $= 6-14$), with the data comprising a total number of 629 individuals who had received a single 201 dose of albendazole. Of the 92 time-series identified, information on the sex of participants was 202 available for 67 time-series (37 from male participants, 24 including a mixture of males and females, 203 and 6 from female participants), with information on mean age and weight available for 79 and 69

C. Whittaker et al. Albendazole Pharmacokinetics 9

204 time-series respectively. Sixteen time-series were from children under the age of 18. Information on 205 whether treatment was taken with a fatty meal was available for 75 time-series (29 received a fatty ²⁰⁶meal, the remainder did not), whilst infection status was available for 91 time-series (48 were from 207 uninfected patient populations, 16 were from individuals with neurocysticercosis, 14 from individuals 208 with echinococcosis, 7 from individuals with onchocerciasis, 3 from individuals with lymphatic 209 filariasis, 2 from individuals with giardiasis and 1 from an individual with hookworm infection). The ²¹⁰median dose received was 400 mg (range 200 mg – 2205 mg). Co-administered drugs included 211 ivermectin $(n=7)$, diethylcarbamazine (DEC, n=7), praziquantel $(n=4)$, ritonavir $(n=2)$, 212 dexamethasone $(n=2)$, amoxicillin $(n=1)$, gentamycin $(n=1)$, metronidazole $(n=1)$, ceftriaxone $(n=1)$, ²¹³levamisole (n=1) and oxantel pamoate (n=1). **Supplementary Table S1 in** *Supplementary S1 File* 214 provides full details of each included study and time-series.

²¹⁵**Pharmacokinetic modelling of albendazole and albendazole sulfoxide dynamics**

216 To each of these collated time-series, we fitted a model describing the dynamics of albendazole and ²¹⁷albendazole sulfoxide concentrations in the blood following receipt of a single oral dose and before a 218 second dose in the case of treatment regimen using multiple doses (see **Fig 2** for model structure and 219 formulation). This model was fitted individually to each time-series within a Bayesian MCMC-based ²²⁰framework (see **Supplementary Fig S1** in *Supplementary S1 File* for individual model fitting results 221 for each time-series). Our results highlighted significant variation in model estimates of key 222 pharmacokinetic parameters including k_{AlbSO} (the half-life of albendazole sulfoxide), the ²²³bioavailability of albendazole (i.e. proportion of administered albendazole absorbed from the gut into 224 the blood), C_{Max400} (peak modelled concentration of albendazole sulfoxide in the blood following 225 receipt of a hypothetical 400 mg dose) and AUC_{400} (total modelled exposure to albendazole sulfoxide 226 following receipt of a hypothetical 400 mg dose of albendazole). Stratifying the modelled 227 pharmacokinetic profiles by various characteristics of the patient population suggested possible 228 systematic pharmacokinetic differences associated with patient- and treatment regimen-related ²²⁹factors, although also extensive between-study variation in dynamics **(Fig 3)**.

²³⁰**Fig 3: Albendazole sulfoxide pharmacokinetic variability, stratified by patient and dosage** 231 **features.** In all panels displayed above, each pale line represents the fitted model output for a single time-series, with the darker lines representing the average of the time-series for a given category. 232 time-series, with the darker lines representing the average of the time-series for a given category.
233 Factors explored were (A) Sex; (B) Feeding Status (according to whether groups had received the 233 Factors explored were **(A)** Sex; **(B)** Feeding Status (according to whether groups had received the 234 single dose of albendazole alongside a fatty meal or not); **(C)** Dose (with time-series crudely 234 single dose of albendazole alongside a fatty meal or not); **(C)** Dose (with time-series crudely categorised into high/low strata based on whether the dose was higher or lower than 400 mg); **(D)** 235 categorised into high/low strata based on whether the dose was higher or lower than 400 mg); **(D)** 236 Infection Status (defined as per the paper associated with each time-series as whether the patient 236 Infection Status (defined as per the paper associated with each time-series as whether the patient 237 population were receiving treatment for a known infection or not); (**E**) Co-Administered Drugs (i.e. 237 population were receiving treatment for a known infection or not); **(E)** Co-Administered Drugs (i.e. 238 whether albendazole was delivered alone or in tandem with other drugs); and **(F)** Age Group, defined 238 whether albendazole was delivered alone or in tandem with other drugs); and **(F)** Age Group, defined 239 based on whether the average age of the patients was under 18 vears old (children) or >18 vears 239 based on whether the average age of the patients was under 18 years old (children) or \geq 18 years 240 (adults). (adults).

```
241
```
²⁴²In order to explore these relationships more formally, we carried out a multiple linear regression ²⁴³analysis to assess which of the factors in **Fig 3** were statistically associated with differences in these ²⁴⁴pharmacokinetic parameters. The results of this regression are displayed in **Table 1**. Receipt of a fatty 245 meal prior to treatment increased the bioavailability of albendazole by 38% on average $(p<0.01)$ and 246 resulted in a significantly higher peak blood concentration (C_{Max400} being 353 mg/ml higher or 247 almost twice as high in individuals receiving a fatty meal on average, $p<0.01$). Receiving a fatty meal 248 prior to treatment was also associated with a 1.53-fold higher overall AUC_{400} than in fasted 249 individuals ($p<0.01$). Higher doses were associated with reduced albendazole bioavailability (with 250 bioavailablity reducing approximately 1% for each 100 mg increase in dosage, $p=0.03$). We did not 251 observe any significant differences in pharmacokinetic parameters that depended on sex.

252 Parasitic infection was associated with significant differences in pharmacokinetic parameters 253 compared to uninfected individuals. Whilst we did not detect any significant differences when 254 considering infection status as a binary indicator (i.e. whether an individual had a parasitic infection 255 or not), stratifying the infected population further by specific disease revealed significant associations 256 between particular diseases. There was a significant association between neurocysticercosis and 257 albendazole sulfoxide half-life (median 12 hours compared to 10.5 hours in uninfected individuals, $p=0.05$; and significant effects of echinococcosis on bioavailability (increased by 14% in infected 259 compared to uninfected individuals, $p<0.01$) and C_{Max400} and AUC_{400} (increased by 2.7 and 4.0 fold 260 respectively, $p<0.01$ in both instances). We did not observe any significant association between 261 onchocerciasis and the considered pharmacokinetic parameters.

C. Whittaker et al. Albendazole Pharmacokinetics 11

262 As a sensitivity analysis, we repeated the analyses described above controlling for the dose of 263 albendazole received per kilogram of body weight (available only for a subset of the time-series due 264 to a lack of complete information about participants' weight), rather than the raw amount (in mg, not 265 standardised by body weight) given to an individual. All significant associations described above 266 were retained when conducting this subset sensitivity analysis (see **Supplementary S2 Table** in ²⁶⁷*Supplementary File S1*). Additionally, we observed a difference between age groups in the modelled 268 estimates of k_{AlbSO} , with the median half-life of albendazole sulfoxide at 12.4 hours in adults 269 compared to only 8.04 hours in children under the age of 18 years ($p<0.01$).

²⁷⁰We did not detect a significant effect of co-administered drugs on albendazole's pharmacokinetics, 271 though it is important to note that the heterogeneous array of drugs co-administered across the 272 collated dataset, and the comparative paucity of time-series featuring each of the drugs precluded a 273 stratified analysis of each drug individually (as was possible with disease status). This lack of data 274 necessitated combining them into the binary category or yes/no co-administration. The corollary of 275 this is that these analyses were not powered to reliably detect drug-drug interactions with albendazole 276 (which are well documented in the literature).

277

281
282 **Figure 1: PRISMA diagram illustrating the systematic review workflow.** Web of Science and 283 PubMed were searched on 4th July 2019 using the keywords albendazole AND (treatment* OR dose* 283 PubMed were searched on $4th$ July 2019 using the keywords albendazole AND (treatment* OR dose* 284 OR pharma* OR "half-life" OR "half-life"). This produced a total of 5690 results after duplicate 284 OR pharma* OR "half-life" OR "half life"). This produced a total of 5690 results after duplicate
285 removal of which 206 were retained for full text screening 175 of the retained articles were 285 removal, of which 206 were retained for full text screening. 175 of the retained articles were
286 subsequently excluded based on pre-defined exclusion criteria, vielding 32 studies containing 286 subsequently excluded based on pre-defined exclusion criteria, yielding 32 studies containing
287 temporally disaggregated data on albendazole blood concentrations following treatment with a single 287 temporally disaggregated data on albendazole blood concentrations following treatment with a single
288 dose: these 32 references contained a total of 92 time-series measuring albendazole and/or 288 dose; these 32 references contained a total of 92 time-series measuring albendazole and/or 289 albendazole sulfoxide blood concentrations over time in different populations. albendazole sulfoxide blood concentrations over time in different populations.

291

³⁰¹**Figure 2: Schematic representation of the model describing albendazole and albendazole** ³⁰²**sulfoxide dynamics and pharmacokinetics.** A compartmental model consisting of a series of linked 303 ordinary differential equations (ODEs) was developed to simulate the pharmacokinetics of 304 albendazole and its pharmacodynamically-active metabolite, albendazole sulfoxide, in the blood 304 albendazole and its pharmacodynamically-active metabolite, albendazole sulfoxide, in the blood
305 following a single oral dose. (A) Schematic illustrating the model structure and the way in which the 305 following a single oral dose. **(A)** Schematic illustrating the model structure and the way in which the 306 different compartments are linked. **(B)** Overview of the ODEs governing the model, representing the 306 different compartments are linked. **(B)** Overview of the ODEs governing the model, representing the amount of albendazole in the gut and concentration of the drug (and its metabolite albendazole 307 amount of albendazole in the gut and concentration of the drug (and its metabolite albendazole sulfoxide) in the liver and systemic circulation. Note that the received dose is further scaled by a 308 sulfoxide) in the liver and systemic circulation. Note that the received dose is further scaled by a
309 bioavailablity parameter not shown here – see *Supplementary Information* Section "Mathematical ³⁰⁹bioavailablity parameter not shown here – see *Supplementary Information* **Section "Mathematical** ³¹⁰**Model of Albendazole and Albendazole Sulfoxide Dynamics"** for further details and full description of the model equations.

³¹⁹**Figure 3: Albendazole sulfoxide pharmacokinetic variability, stratified by patient and dosage features.** In all panels displayed above, each pale line represents the fitted model output for a single time-series, with the darker lines representing the average of the time-series for a given category. 321 time-series, with the darker lines representing the average of the time-series for a given category.
322 Factors explored were (A) Sex; (B) Feeding Status (according to whether groups had received the 322 Factors explored were **(A)** Sex; **(B)** Feeding Status (according to whether groups had received the single dose of albendazole alongside a fatty meal or not): **(C)** Dose (with time-series crudely 323 single dose of albendazole alongside a fatty meal or not); **(C)** Dose (with time-series crudely categorised into high/low strata based on whether the dose was higher than 400 mg); **(D)** Infection 324 categorised into high/low strata based on whether the dose was higher than 400 mg); **(D)** Infection 325 Status (defined as per the paper associated with each time-series as whether the patient population 325 Status (defined as per the paper associated with each time-series as whether the patient population 326 were receiving treatment for a known infection or not): (E) Co-Administered Drugs (i.e. whether 326 were receiving treatment for a known infection or not); **(E)** Co-Administered Drugs (i.e. whether albendazole was delivered alone or in tandem with other drugs); and **(F)** Age Group, defined based on 327 albendazole was delivered alone or in tandem with other drugs); and **(F)** Age Group, defined based on whether the average age of the patients was under 18 years old (children) or \geq 18 years (adults). whether the average age of the patients was under 18 years old (children) or ≥18 years (adults).

329

-
- 335

³³⁶**Table 1: Regression outputs relating pharmacokinetic properties to characteristics.** Inferred

337 parameters from the fitted pharmacokinetic curves, specifically albendazole bioavailability,
338 albendazole sulfoxide half-life, AUC and C_{Max} were regressed onto various patient population

338 albendazole sulfoxide half-life, *AUC* and *C_{Max}* were regressed onto various patient population demographic and treatment metadata.

demographic and treatment metadata.

C. Whittaker et al. Albendazole Pharmacokinetics 16

³⁴³**Discussion**

³⁴⁴Despite widespread usage, significant uncertainty surrounds the factors underlying variation in the 345 pharmacokinetics of albendazole. Whilst other studies have previously examined these factors 346 individually (e.g. [23,28–31] amongst others), a systematic analysis of different factors together 347 remained outstanding. Integrating the results of a systematic review of the literature with a ³⁴⁸mathematical model of albendazole/albendazole sulfoxide dynamics, our work highlights the 349 extensive inter-individual pharmacokinetic variation in albendazole's dynamics, and the impact that a 350 number of different factors has in shaping the pharmacokinetic profile of the drug (and its metabolite) 351 in the blood following receipt of a single oral dose. Importantly, our results suggest that these 352 different factors influence different pharmacokinetic parameters, and hence alter different aspects of 353 the pharmacokinetic profile of the drug in the blood.

354 In-keeping with previous work [22,23,32–34], consumption of a fatty meal prior to receiving the dose ³⁵⁵was associated with increased bioavailability of albendazole, increasing the amount absorbed into the 356 body (and concomitantly elevating the *AUC* and *C_{Max}* values achieved), a phenomenon thought to be 357 attributed to changes in the drug's solubility (previously shown to be the rate-limiting step in 358 albendazole's bioavailablity and absorption [27]) when delivered alongside a fatty meal [34]. Whilst 359 prior results from the literature have suggested (modest) differences between men and women in 360 albendazole's pharmacokinetics (specifically with regards to the *AUC* and *C_{Max}* [19]), we did not 361 observe any statistically significant differences here. However, important caveats to our results are 362 that the lack of individual data in many cases precluded examination of men and women separately. ³⁶³Therefore, we constructed a crude proxy for comparison (between men and groups in which the 364 population comprised mixtures of men and women), which may not have been powered to detect the ³⁶⁵(minor) differences previously reported [19]. We observed a small but significant effect of the dose of 366 albendazole received on the bioavailability of the drug, with bioavailability decreasing as the dose ³⁶⁷increased. This is consistent with the well-described induction by albendazole of enzymes responsible ³⁶⁸for its own metabolism [35]. Together, our results also suggest that different factors impact different 369 pharmacokinetic properties of albendazole and albendazole sulfoxide. For example, whilst receipt of a

C. Whittaker et al. **Albendazole Pharmacokinetics** 17

370 fatty meal was associated with increases to bioavailability, *AUC* and *C_{Max}*, age was significantly 371 associated with albendazole sulfoxide half-life (when controlling for dosage per kilogram of body 372 weight).

373 Perhaps most interestingly, our analyses suggested significant effects of parasitic infection on 374 albendazole pharmacokinetics, with the exact impact dependent on the infection being considered. 375 Previous work in sheep has highlighted that gastrointestinal nematode infection can influence the 376 kinetics of albendazole and albendazole sulfoxide, leading to increased *AUC* values [36]. Other work ³⁷⁷has noted increased rates of transformation from albendazole to albendazole sulfoxide in infected 378 compared to uninfected sheep [37], though this has been inconsistently observed and the exact 379 influence (or lack thereof) likely depends on the particular infecting parasite [38]. Work in humans ³⁸⁰has suggested that the precise impact of infection depends on the interaction between the drug ³⁸¹(particularly its absorption and elimination) and the infecting parasite's impact on the host. For 382 example, whilst recent work comparing the pharmacokinetics of albendazole in uninfected and ³⁸³*Wuchereria bancrofti*-infected adults showed no differences [24], previous work exploring ³⁸⁴albendazole kinetics in patients with echinococcosis demonstrated delayed absorption and impaired 385 elimination of the drug (with this latter effect contributing to increases in the *AUC* of albendazole 386 sulfoxide, particularly in patients with hepatic obstruction due to the disease) [39]. In-keeping with 387 these results, we observed a significant effect of echinococcosis on albendazole's pharmacokinetic 388 parameters, with infection associated with increases to the bioavailability, C_{Max} and *AUC* of the drug. ³⁸⁹By contrast, we observed no significant effect of onchocerciasis on albendazole's pharmacokinetics. ³⁹⁰For neurocysticercosis, we observed alterations to the apparent half-life of albendazole sulfoxide. 391 However, these results should be interpreted with caution. Sample sizes for each of the individual ³⁹²infections were small; for example, the largest was for echinococcosis with 14 time-series drawn from ³⁹³a total of four studies. The estimates presented here are therefore uncertain, and it is possible that 394 study-specific variation not accounted for might explain the observed results. Relatedly, whilst we 395 attempted to control for co-administered drugs, our ability to do this was limited (see below). It is,

C. Whittaker et al. Albendazole Pharmacokinetics 18

396 therefore, possible that the results presented here might be confounded by the receipt of treatment for 397 an infection that is not described in the reference.

³⁹⁸There are a number of limitations to the analyses presented here. Firstly, and perhaps most notably, 399 the available data in the literature were highly heterogeneous, involving a diversity of treatment 400 regimens (i.e. other co-administered drugs) and patients (i.e. characteristics), with data available at 401 different levels of aggregation (i.e. individual vs. average profiles). This constraint limits the 402 statistical power of our analyses to characterise the effects of different individual drugs on 403 albendazole's pharmacokinetics. Whilst our binary indicator for co-administered drugs was not found 404 to be significantly associated with any of the pharmacokinetic parameters explored here, numerous 405 interactions between albendazole and other drugs such as cimetidine [20], azithromycin [40] and 406 various anti-epileptic drugs [41] are well-documented in the literature. It is also important to note the 407 overall paucity of available data upon which the inferences presented here are based. Whilst 408 albendazole sulfoxide data were available for all 92 time-series considered here, data on albendazole's 409 pharmacokinetics was only available for 15 time-series; and in no cases was comparable information 410 relevant to the drug's metabolism (such as liver function) available.

⁴¹¹In addition to these constraints posed by population-level data, the results presented here are limited 412 in that they only describe the pharmacokinetic dynamics following treatment with a single dose of 413 albendazole. This holds programmatic relevance given usage of albendazole in MDA programmes 414 targeting STH [42] and/or LF [43] amongst others but other treatment regimen exist, most notably the 415 use of albendazole in dedicated clinical settings to treat individuals for diseases such as cysticercosis 416 and echinococcosis. These regimens typically utilise multiple doses delivered over consecutive days. 417 Previous results have indicated that albendazole appears to induce its own metabolism through ⁴¹⁸induction of key enzymes in the liver [25], and that multiple doses given over sequential days can lead 419 to changes in pharmacokinetic properties over the course of multiple dose regimen; specifically, 420 reductions in the maximum blood concentrations of albendazole sulfoxide reached following each 421 dose [44]. However, the magnitude of this effect and the frequency of dosing required to elicit ⁴²²pharmacologically-relevant reductions in blood concentrations remain far from clear and have, to

C. Whittaker et al. **Albendazole Pharmacokinetics** 19

423 date, been addressed in only a limited number of studies. Exploration of this phenomenon and its 424 consequences for anthelmintic treatment regimens using multiple doses of the drug would require 425 both further clinical research and an extension of the mathematical model developed here, and likely 426 represents an instructive avenue of future investigation. Similarly, extensions of the model to include ⁴²⁷infrequent but reported pharmacokinetic phenomena associated with albendazole treatment, such as ⁴²⁸biphasic pharmacokinetic profiles (thought possibly to be a product of inter-individual variation in 429 frequency of gastric emptying affecting release of ingested albendazole into the gut, as well as other 430 related characteristics $[45]$), would also likely provide new insight.

⁴³¹The availability of studies explicitly exploring the pharmacokinetics of drugs used to treat NTDs is ⁴³²limited [46]. Despite the limitations described above, our work begins to address this gap for 433 albendazole. It suggests potential useful avenues for improvements to programmatic delivery of ⁴³⁴albendazole, and perhaps more importantly, highlights the existence of significant inter-individual 435 variation in albendazole pharmacokinetics. Whilst we provide insight into some of the factors 436 underlying this variation, further quantification and exploration will be essential. This is particularly 437 crucial for understanding and interpreting the results of studies exploring programmatic usage of the 438 drug to treat parasitic infections. Having an understanding of the degree of inter-individual variation 439 will be vital for establishing whether observed sub-optimal responses to the drug are due to parasitic 440 factors (e.g. possible resistance potentially developed through cumulative exposure to treatment over ⁴⁴¹multiple rounds [47]) or, instead, simply reflect a high degree of variation between individuals in total 442 exposure to the drug (and hence anti-parasitic effect) that follows ingestion of the same oral dose. ⁴⁴³Indeed, previous work has demonstrated a high degree of community-level variation in the impacts of ⁴⁴⁴ivermectin distribution campaigns to treat onchocerciasis in Ghana, even across communities 445 characterised by similar histories of ivermectin exposure [48], highlighting the need to understand 446 patterns of variation in drug responses (both at the individual and community level) if the underlying 447 causes are to be accurately determined. Together, these results support and underscore recent calls ⁴⁴⁸highlighting the need for the collection, collation and analysis of individual participant data (IPD) to ⁴⁴⁹generate robust evidence on efficacy and safety of anti-parasitic treatment regimens [49]. Given the

C. Whittaker et al. **Albendazole Pharmacokinetics** 20

⁴⁵³**Data and Code Availability:** All data collated as part of this study, as well as the analytical code 454 used to generate the analyses reported in the Main Text and Supplementary File can be found at the

455 following link: https://github.com/cwhittaker1000/albendazole_pk.

⁴⁵⁶**Acknowledgements:** We deeply thank Dr Annette C. Kuesel for her hugely insightful and helpful

457 comments on earlier versions of this manuscript, which have materially improved and contributed to 458 the work now presented here.

⁴⁵⁹**Funding Statement:**

⁴⁶⁰C.W. and M.G.B. acknowledge funding from the Medical Research Council (MRC) Centre for Global

⁴⁶¹Infectious Disease Analysis (MR/R015600/1), jointly funded by the UK MRC and the UK Foreign,

462 Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is ⁴⁶³also part of the European and Developing Countries Clinical Trials Partnership (EDCTP2)

464 programme supported by the European Union.

⁴⁶⁵**Authors Contributions:**

Charlie Whittaker: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Visualization, Writing – Original Draft Preparation; **Cédric B. Chesnais:** Resources, Writing – Review & Editing; **Sébastien D.S. Pion:** Writing – Review & Editing; **Joseph Kamgno:** Writing – Review & Editing; **Martin Walker:** Resources, Writing – Review & Editing; **Maria-Gloria Basáñez:** Conceptualization, Funding Acquisition, Project Administration, Resources, Supervision, Writing – Review & Editing; **Michel Boussinesq:** Conceptualization, Project 472 Administration, Resources, Supervision, Writing – Review & Editing.

- **S1 Text: Data Extraction, Collation and Initial Processing**
- *Systematic Review References & Associated Metadata*
- **S1 Table: Studies collated through the systematic review and their associated metadata**
- **S2 Text: Model Construction, Fitting and Inference**
- *Mathematical Model of Albendazole and Albendazole Sulfoxide Dynamics*
- *Model Fitting and Inferential Framework*
- *Pharmacokinetic Parameter Estimation and Multiple Linear Regression Modelling*
- **S1 Figure: Results of model fitting and calibration to data collated through the systematic review.**
- **S2 Table: Multiple linear regression results relating pharmacokinetic properties to study**
- **characteristics when controlling for dosage per kilogram of body weight instead of raw dosage**
- **amount in milligrams**
- **Supplementary References**

⁴⁸⁹**References**

- 490 1. Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H, et al. Effects of albendazole
491 treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 491 treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry.
492 2008:79: 1050–1055. doi:10.1136/innp.2008.144899 ⁴⁹²2008;79: 1050–1055. doi:10.1136/jnnp.2008.144899
- 493 2. Teggi A, Lastilla MG, De Rosa F. Therapy of human hydatid disease with mebendazole and
494 albendazole. Antimicrob Agents Chemother. 1993;37: 1679–1684. doi:10.1128/AAC.37.8.1679 ⁴⁹⁴albendazole. Antimicrob Agents Chemother. 1993;37: 1679–1684. doi:10.1128/AAC.37.8.1679
- 495 3. Vlaminck J, Cools P, Albonico M, Ame S, Ayana M, Cringoli G, et al. Therapeutic efficacy of albendazole against soil-transmitted helminthiasis in children measured by five diagnostic 496 albendazole against soil-transmitted helminthiasis in children measured by five diagnostic
497 methods. PLoS Negl Trop Dis. 2019:13: e0007471. doi:10.1371/iournal.pntd.0007471 ⁴⁹⁷methods. PLoS Negl Trop Dis. 2019;13: e0007471. doi:10.1371/journal.pntd.0007471
- 498 4. Pion SDS, Chesnais CB, Weil GJ, Fischer PU, Missamou F, Boussinesq M. Effect of 3 years of
499 biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted 499 biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted
500 belminth infections: a community-based study in Republic of the Congo. Lancet Infect Dis. 500 helminth infections: a community-based study in Republic of the Congo. Lancet Infect Dis.
501 2017:17: 763–769. doi:10.1016/S1473-3099(17)30175-5 ⁵⁰¹2017;17: 763–769. doi:10.1016/S1473-3099(17)30175-5
- 502 5. Macfarlane CL, Budhathoki SS, Johnson S, Richardson M, Garner P. Albendazole alone or in
503 combination with microfilaricidal drugs for lymphatic filariasis. Cochrane Database Syst Rev. 503 combination with microfilaricidal drugs for lymphatic filariasis. Cochrane Database Syst Rev.
504 2019:1: CD003753. doi: 10.1002/14651858.CD003753.pub4 ⁵⁰⁴2019;1: CD003753. doi: 10.1002/14651858.CD003753.pub4
- 505 6. Dubray CL, Sircar AD, Beau de Rochars VM, Bogus J, Direny AN, Ernest JR, et al. Safety and
506 fficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug 506 efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug
507 administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-507 administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-
508 community study. PLoS Negl Trop Dis. 2020;14: e0008298. 508 randomized, community study. PLoS Negl Trop Dis. 2020;14: e0008298. 509 doi:10.1371/JOURNAL.PNTD.0008298
- 510 7. Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA, Magesa SM.
511 Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with 511 Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with
512 ivermectin and albendazole on infection and transmission. PLoS Negl Trop Dis. 2010:4: e696. 512 ivermectin and albendazole on infection and transmission. PLoS Negl Trop Dis. 2010;4: e696.
513 doi:10.1371/journal.pntd.0000696 ⁵¹³doi:10.1371/journal.pntd.0000696
- 514 8. Klion AD, Massougbodji A, Horton J, Ekoué S, Lanmasso T, Ahouissou NL, et al. Albendazole
515 in human loiasis: results of a double-blind. placebo-controlled trial. J Infect Dis. 1993:168: 202– 515 in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis. 1993;168: 202–
516 206. doi:10.1093/infdis/168.1.202 ⁵¹⁶206. doi:10.1093/infdis/168.1.202
- 517 9. Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis. 1999;29: 680–682. ⁵¹⁸diethylcarbamazine treatment. Clin Infect Dis. 1999;29: 680–682.

- 519 10. Arrey-Agbor DB, Nana-Djeunga HC, Mogoung-Wafo AE, Mafo M, Danwe C, Kamgno J. Case
520 report: Probable case of spontaneous encephalopathy due to loiasis and dramatic reduction of 520 report: Probable case of spontaneous encephalopathy due to loiasis and dramatic reduction of
521 Loa loa microfilariaemia with prolonged repeated courses of albendazole. Am J Trop Med Hyg. 521 Loa loa microfilariaemia with prolonged repeated courses of albendazole. Am J Trop Med Hyg.
522 2018;99: 112–115. ⁵²²2018;99: 112–115. 523 11. Kamgno J, Nguipdop-Djomo P, Gounoue R, Téjiokem M, Kuesel AC. Effect of two or six doses
524 800 mg of albendazole every two months on Loa loa microfilaraemia: A double blind. 524 800 mg of albendazole every two months on Loa loa microfilaraemia: A double blind,
525 analomized, placebo-controlled trial. PLoS Negl Trop Dis. 2016;10: e0004492. ⁵²⁵randomized, placebo-controlled trial. PLoS Negl Trop Dis. 2016;10: e0004492. 526 12. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M.
527 Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for 527 Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for
528 Loa loa infection. Lancet. 1997:350: 18–22. doi:10.1016/S0140-6736(96)11094-1 ⁵²⁸Loa loa infection. Lancet. 1997;350: 18–22. doi:10.1016/S0140-6736(96)11094-1 529 13. Jung-Cook H. Pharmacokinetic variability of anthelmintics: implications for the treatment of
530 neurocysticercosis. Expert Rev Clin Pharmacol. 2012:5: 21–30. doi:10.1586/ECP.11.72 ⁵³⁰neurocysticercosis. Expert Rev Clin Pharmacol. 2012;5: 21–30. doi:10.1586/ECP.11.72 531 14. Del Brutto OH. Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging
532 analysis of 17 patients. J Neurol Neurosurg Psychiatry. 1997;62: 659–661. 532 analysis of 17 patients. J Neurol Neurosurg Psychiatry. 1997;62: 659–661.
533 doi:10.1136/jnnp.62.6.659 ⁵³³doi:10.1136/jnnp.62.6.659 534 15. García HH, Evans CAW, Nash TE, Takayanagui OM, White AC Jr, Botero D, et al. Current
535 consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15: 747–756. 535 consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15: 747–756.
536 doi:10.1128/CMR.15.4.747-756.2002 ⁵³⁶doi:10.1128/CMR.15.4.747-756.2002 537 16. Mrus J, Baeten B, Engelen M, Silber SA. Efficacy of single-dose 500 mg mebendazole in soil-538 transmitted helminth infections: a review. J Helminthol. 2018;92: 269–278. 539 doi:10.1017/S0022149X17000426 540 17. Humphries D, Nguyen S, Kumar S, Quagraine JE, Otchere J, Harrison LM, et al. Effectiveness
541 of albendazole for hookworm varies widely by community and correlates with nutritional 541 of albendazole for hookworm varies widely by community and correlates with nutritional
542 factors: A cross-sectional study of school-age children in Ghana. Am J Trop Med Hyg. 2017;96: 542 factors: A cross-sectional study of school-age children in Ghana. Am J Trop Med Hyg. 2017;96:
543 347–354. doi:10.4269/aitmh.16-0682 ⁵⁴³347–354. doi:10.4269/ajtmh.16-0682 544 18. Basáñez M-G, French MD, Walker M, Churcher TS. Paradigm lost: how parasite control may
545 alter pattern and process in human helminthiases. Trends Parasitol. 2012:28: 161-171. 545 alter pattern and process in human helminthiases. Trends Parasitol. 2012;28: 161–171.
546 doi:10.1016/J.PT.2012.02.004 ⁵⁴⁶doi:10.1016/J.PT.2012.02.004
- 547 19. Mirfazaelian A, Dadashzadeh S, Rouini MR. Effect of gender in the disposition of albendazole
548 metabolites in humans. Eur J Clin Pharmacol. 2002:58: 403-408. doi:10.1007/s00228-002-0488metabolites in humans. Eur J Clin Pharmacol. 2002;58: 403-408. doi:10.1007/s00228-002-0488-8 549

C. Whittaker et al. **Albendazole Pharmacokinetics** 24

550 20. Schipper HG, Nagy J, Van Boxtel CJ, Koopmans RP, Kager PA, Butter JJ. Effect of dose
551 increase or cimetidine co-administration on albendazole bioavailability. Am J Trop Med Hyg. 551 increase or cimetidine co-administration on albendazole bioavailability. Am J Trop Med Hyg.
552 2000;63: 270–273. doi:10.4269/ajtmh.2000.63.270 ⁵⁵²2000;63: 270–273. doi:10.4269/ajtmh.2000.63.270 553 21. Awadzi K, Edwards G, Duke BOL, Opoku NO, Attah SK, Addy ET, et al. The co-administration
554 of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca 554 of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca
555 volvulus. Ann Trop Med Parasitol. 2003:97: 165–178. doi:10.1179/000349803235001697 ⁵⁵⁵volvulus. Ann Trop Med Parasitol. 2003;97: 165–178. doi:10.1179/000349803235001697 556 22. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with
557 fatty meal. Eur J Clin Pharmacol. 1988:34: 315–317. doi: 10.1007/BF00540964 557 fatty meal. Eur J Clin Pharmacol. 1988;34: 315–317. doi: 10.1007/BF00540964
558 23. Mares SS, Jung CH, López AT, González-Esquivel DF. Influence of a Mexic 558 23. Mares SS, Jung CH, López AT, González-Esquivel DF. Influence of a Mexican diet on the
559 bioavailability of albendazole. Basic Clin Pharmacol Toxicol. 2005:97: 122–124. 559 bioavailability of albendazole. Basic Clin Pharmacol Toxicol. 2005;97: 122–124.
560 doi:10.1111/j.1742-7843.2005.pto_172.x ⁵⁶⁰doi:10.1111/j.1742-7843.2005.pto_172.x 561 24. Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Méité A, et al. Pharmacokinetics,
562 safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and 562 safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and
563 ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. PLoS 563 ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. PLoS
564 Negl Trop Dis. 2019;13: e0007325. doi:10.1371/journal.pntd.0007325 ⁵⁶⁴Negl Trop Dis. 2019;13: e0007325. doi:10.1371/journal.pntd.0007325 565 25. Steiger U, Cotting J, Reichen J. Albendazole treatment of echinococcosis in humans: effects on
566 microsomal metabolism and drug tolerance. Clin Pharmacol Ther. 1990;47: 347–353. 566 microsomal metabolism and drug tolerance. Clin Pharmacol Ther. 1990;47: 347–353.
567 doi:10.1038/clpt.1990.38 ⁵⁶⁷doi:10.1038/clpt.1990.38 568 26. Lawrenz A, Eglit S, Kroker R. The metabolism of albendazole in the isolated perfused intestine
569 of rats. Dtsch Tierarztl Wochenschr. 1992:99: 416–418. of rats. Dtsch Tierarztl Wochenschr. 1992;99: 416–418. 570 27. Jung H, Medina L, García L, Fuentes I, Moreno-Esparza R. Absorption studies of albendazole
571 and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J 571 and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J
572 Pharm Pharmacol. 1998:50: 43–48. doi:10.1111/i.2042-7158.1998.tb03303.x ⁵⁷²Pharm Pharmacol. 1998;50: 43–48. doi:10.1111/j.2042-7158.1998.tb03303.x 573 28. Jung H, Sánchez M, González-Astiazarán A, Martínez JM, Suástegui R, González-Esquivel DF.
574 Clinical pharmacokinetics of albendazole in children with neurocysticercosis. Am J Ther. 574 Clinical pharmacokinetics of albendazole in children with neurocysticercosis. Am J Ther.
575 1997:4: 23–26. doi: 10.1097/00045391-199701000-00005 ⁵⁷⁵1997;4: 23–26. doi: 10.1097/00045391-199701000-00005 576 29. Pengsaa K, Na-Bangchang K, Limkittikul K, Kabkaew K, Lapphra K, Sirivichayakul C, et al.
577 Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with 577 Bharmacokinetic investigation of albendazole and praziquantel in Thai children infected with
578 Giardia intestinalis. Ann Trop Med Parasitol. 2004:98: 349–357. ⁵⁷⁸Giardia intestinalis. Ann Trop Med Parasitol. 2004;98: 349–357. 579 doi:10.1179/000349804225003398

C. Whittaker et al. **Albendazole Pharmacokinetics** 25

- 580 30. Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtel CJ, Kager PA. Effect of grapefruit
581 iuice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg. 581 juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg.
582 2002;66: 260–263. doi:10.4269/ajtmh.2002.66.260 ⁵⁸²2002;66: 260–263. doi:10.4269/ajtmh.2002.66.260
- 583 31. Mirfazaelian A, Rouini MR, Dadashzadeh S. Dose dependent pharmacokinetics of albendazole
584 in human. Biopharm Drug Dispos. 2002:23: 379–383. doi:10.1002/bdd.327 ⁵⁸⁴in human. Biopharm Drug Dispos. 2002;23: 379–383. doi:10.1002/bdd.327
- 585 32. Ochoa D, Saiz-Rodríguez M, González-Rojano E, Román M, Sánchez-Rojas S, Wojnicz A, et al.
586 High-fat breakfast increases bioavailability of albendazole compared to low-fat breakfast: 586 High-fat breakfast increases bioavailability of albendazole compared to low-fat breakfast:
587 Single-dose study in healthy subjects. Front Pharmacol. 2021;12: 664465. 587 Single-dose study in healthy subjects. Front Pharmacol. 2021;12: 664465. 588 doi: 10.3389/fphar.2021.664465
- 589 33. Awadzi K, Hero M, Opoku NO, Büttner DW, Coventry PA, Prime MA, et al. The chemotherapy
590 of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis; 590 of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis;
591 effects of food and pretreatment with ivermectin on drug response and pharmacokinetics. Trop 591 effects of food and pretreatment with ivermectin on drug response and pharmacokinetics. Trop
592 Med Parasitol. 1994;45: 203–208. Med Parasitol. 1994;45: 203-208.
- ⁵⁹³34. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62: 1481–1502. ⁵⁹⁴doi:10.2165/00003495-200262100-00005
- 595 35. Souhaili-el Amri H, Fargetton X, Benoit E, Totis M, Batt AM. Inducing effect of albendazole on rat liver drug-metabolizing enzymes and metabolite pharmacokinetics. Toxicol Appl Pharmacol. 596 rat liver drug-metabolizing enzymes and metabolite pharmacokinetics. Toxicol Appl Pharmacol.
597 1988:92: 141–149. doi: 10.1016/0041-008x(88)90236-0 ⁵⁹⁷1988;92: 141–149. doi: 10.1016/0041-008x(88)90236-0
- 598 36. Alvarez LI, Sánchez SF, Lanusse CE. Modified plasma and abomasal disposition of albendazole
599 in nematode-infected sheep. Vet Parasitol. 1997;69: 241–253. doi:10.1016/S0304-599 in nematode-infected sheep. Vet Parasitol.
600 4017(96)01118-1 ⁶⁰⁰4017(96)01118-1
- 601 37. Skálová L, Krízová V, Cvilink V, Szotáková B, Storkánová L, Velík J, et al. Mouflon (Ovis
602 musimon) dicrocoeliosis: effects of parasitosis on the activities of biotransformation enzymes 602 musimon) dicrocoeliosis: effects of parasitosis on the activities of biotransformation enzymes
603 and albendazole metabolism in liver. Vet Parasitol. 2007;146: 254–262. 603 and albendazole metabolism in liver. Vet Parasitol. 2007;146: 254–262. ⁶⁰⁴doi:10.1016/j.vetpar.2007.02.026
- 605 38. McKellar QA, Jackson F, Coop RL, Baggot JD. Plasma profiles of albendazole metabolites after
606 administration of netobimin and albendazole in sheep: effects of parasitism and age. Br Vet J. 606 administration of netobimin and albendazole in sheep: effects of parasitism and age. Br Vet J.
607 1993;149: 101-113. doi: 10.1016/S0007-1935(05)80213-1 ⁶⁰⁷1993;149: 101–113. doi: 10.1016/S0007-1935(05)80213-1
- 608 39. Cotting J, Zeugin T, Steiger U, Reichen J. Albendazole kinetics in patients with echinococcosis:
609 delaved absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol. 1990:38: 605– 609 delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol. 1990;38: 605–
610 608. doi: 10.1007/BF00278590 608. doi: 10.1007/BF00278590

611 40. Amsden GW, Gregory TB, Michalak CA, Glue P, Knirsch CA. Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and 612 azithromycin and the combination of ivermectin and albendazole when administered alone and
613 concurrently in healthy volunteers. Am J Trop Med Hyg. 2007:76: 1153–1157. 613 concurrently in healthy volunteers. Am J Trop Med Hyg. 2007;76: 1153–1157.
614 doi:10.4269/ajtmh.2007.76.1153 ⁶¹⁴doi:10.4269/ajtmh.2007.76.1153

- 615 41. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol.
616 2006:61: 246–255. doi:10.1111/i.1365-2125.2005.02529.x ⁶¹⁶2006;61: 246–255. doi:10.1111/j.1365-2125.2005.02529.x
- 617 42. Echazú A, Juarez M, Vargas PA, Cajal SP, Cimino RO, Heredia V, et al. Albendazole and
618 ivermectin for the control of soil-transmitted helminths in an area with high prevalence of 618 ivermectin for the control of soil-transmitted helminths in an area with high prevalence of 619 Strongyloides stercoralis and hookworm in northwestern Argentina: A community-based 619 Strongyloides stercoralis and hookworm in northwestern Argentina: A community-based
620 pragmatic study. PLoS Negl Trop Dis. 2017;11: e0006003. doi:10.1371/journal.pntd.0006003 ⁶²⁰pragmatic study. PLoS Negl Trop Dis. 2017;11: e0006003. doi:10.1371/journal.pntd.0006003
- 621 43. Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, et al. The safety of double-
622 and triple-drug community mass drug administration for lymphatic filariasis: A multicenter. 622 and triple-drug community mass drug administration for lymphatic filariasis: A multicenter,
623 open-label, cluster-randomized study. PLoS Med. 2019;16: e1002839. 623 open-label, cluster-randomized study. PLoS Med. 2019;16: e1002839. ⁶²⁴doi:10.1371/journal.pmed.1002839
- 625 44. Hoaksey PE, Awadzi K, Ward SA, Coventry PA, Orme ML, Edwards G. Rapid and sensitive
626 method for the determination of albendazole and albendazole sulphoxide in biological fluids. J 626 method for the determination of albendazole and albendazole sulphoxide in biological fluids. J
627 chromatogr. 1991;566: 244–249. doi:10.1016/0378-4347(91)80131-U ⁶²⁷chromatogr. 1991;566: 244–249. doi:10.1016/0378-4347(91)80131-U
- ⁶²⁸45. Davies NM, Takemoto JK, Brocks DR, Yáñez JA. Multiple peaking phenomena in 629 pharmacokinetic disposition. Clin Pharmacokinet. 2010;49: 351–377. doi:10.2165/11319320-
630 000000000-00000 ⁶³⁰000000000-00000
- 631 46. Verrest L, Dorlo TPC. Lack of clinical pharmacokinetic studies to optimize the treatment of
632 besteed tropical diseases: A systematic review. Clin Pharmacokinet. 2017:56: 583–606. 632 neglected tropical diseases: A systematic review. Clin Pharmacokinet. 2017;56: 583–606.
633 doi:10.1007/s40262-016-0467-3 ⁶³³doi:10.1007/s40262-016-0467-3
- 634 47. Walker M, Cools P, Albonico M, Ame SM, Ayana M, Dana D, et al. Individual responses to a
635 single oral dose of albendazole indicate reduced efficacy against soil-transmitted helminths in an 635 single oral dose of albendazole indicate reduced efficacy against soil-transmitted helminths in an
636 area with high drug pressure. PLoS Negl Trop Dis. 2021;15: e0009888. 636 area with high drug pressure. PLoS Negl Trop Dis. 2021;15: e0009888. ⁶³⁷doi:10.1371/JOURNAL.PNTD.0009888
- 638 48. Churcher TS, Pion SDS, Osei-Atweneboana MY, Prichard RK, Awadzi K, Boussinesq M, et al.
639 Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proc Natl 639 Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proc Natl
640 Acad Sci U S A. 2009:106:16716-16721. doi:10.1073/PNAS.0906176106 ⁶⁴⁰Acad Sci U S A. 2009;106: 16716–16721. doi:10.1073/PNAS.0906176106

-
- 641 49. Walker M, Freitas LT, Halder JB, Brack M, Keiser J, King CH, et al. Improving anthelmintic
642 treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of
- treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of
643 individual participant data. Wellcome Open Res. 2022;7: 5. 643 individual participant data. Wellcome Open Res. 2022;7: 5.
- ⁶⁴⁴doi:10.12688/wellcomeopenres.17468.1